{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:09:56Z","timestamp":1794330596339,"version":"4.9.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gemcitabine is a broadly prescribed chemotherapy, the use of which can be limited by renal adverse events, including thrombotic microangiopathy (TMA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This study evaluated the efficacy of eculizumab, a monoclonal antibody targeting the terminal complement pathway, in patients with gemcitabine-induced TMA (G-TMA). We conducted an observational, retrospective, multicenter study in 5 French centres, between 2011 and 2016.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twelve patients with a G-TMA treated by eculizumab were included. The main characteristics were acute renal failure (100%), including stage 3 acute kidney injury (AKI, 58%) and renal replacement therapy (17%), hypertension (92%) and diffuse oedema (83%). Eculizumab was started after a median of 15\u2009days (range 4\u201344) following TMA diagnosis. A median of 4 injections of eculizumab was performed (range 2\u201322). Complete hematological remission was achieved in 10 patients (83%) and blood transfusion significantly decreased after only one injection of eculizumab (median of 3 packed red blood cells (range 0\u201310) before treatment vs 0 (range 0\u20131) after one injection, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Two patients recovered completely renal function (17%), and 8 achieved a partial remission (67%). Compared to a control group of G-TMA without use of eculizumab, renal outcome was more favourable. At the end of the follow up, median eGFR was 45 vs 33\u2009ml\/min\/1.73m<jats:sup>2<\/jats:sup> respectively in the eculizumab group and in the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results suggest that eculizumab is efficient on haemolysis and reduces transfusion requirement in G-TMA. Moreover, eculizumab may improve renal function recovery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02470-3","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:02:46Z","timestamp":1626825766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre"],"prefix":"10.1186","volume":"22","author":[{"given":"Maximilien","family":"Grall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Daviet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie Jourde","family":"Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Provot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Presne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Coindre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Pouteil-Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Karras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Guerrot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Veyradier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Fr\u00e9meaux-Bacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Coppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Grang\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"2470_CR1","doi-asserted-by":"publisher","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","volume":"3","author":"JA Kremer Hovinga","year":"2017","unstructured":"Kremer Hovinga JA, Coppo P, L\u00e4mmle B, et al. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primer. 2017;3:17020.","journal-title":"Nat Rev Dis Primer"},{"issue":"4","key":"2470_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616\u20138.","journal-title":"Blood."},{"issue":"1","key":"2470_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/BF00873232","volume":"12","author":"ES Casper","year":"1994","unstructured":"Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2\u2032-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Investig New Drugs. 1994;12(1):29\u201334.","journal-title":"Investig New Drugs"},{"issue":"9","key":"2470_CR4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/(SICI)1097-0142(19990501)85:9%3C2023::AID-CNCR21%3E3.0.CO;2-2","volume":"85","author":"MC Fung","year":"1999","unstructured":"Fung MC, Storniolo AM, Nguyen B, et al. A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 1999;85(9):2023\u201332.","journal-title":"Cancer."},{"issue":"3","key":"2470_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0272-6386(99)70194-0","volume":"33","author":"CD Flombaum","year":"1999","unstructured":"Flombaum CD, Mouradian JA, Casper ES, Erlandson RA, Benedetti F. Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine. Am J Kidney Dis. 1999;33(3):555\u201362.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2470_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5414\/CNP71130","volume":"71","author":"I Glezerman","year":"2009","unstructured":"Glezerman I, Kris MG, Miller V, Seshan S, Flombaum CD. Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution. Clin Nephrol. 2009;71(2):130\u20139.","journal-title":"Clin Nephrol"},{"issue":"11","key":"2470_CR7","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","volume":"21","author":"H Izzedine","year":"2006","unstructured":"Izzedine H, Isnard-Bagnis C, Launay-Vacher V, et al. Gemcitabine-induced thrombotic microangiopathy: a systematic review. Nephrol Dial Transplant. 2006;21(11):3038\u201345.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2470_CR8","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/S1470-2045(07)70203-6","volume":"8","author":"M Zupancic","year":"2007","unstructured":"Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 2007;8(7):634\u201341.","journal-title":"Lancet Oncol"},{"issue":"6","key":"2470_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1517\/14740330802374262","volume":"7","author":"CA Dasanu","year":"2008","unstructured":"Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf. 2008;7(6):703\u201316.","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2470_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jca.20213","volume":"24","author":"EM Gore","year":"2009","unstructured":"Gore EM, Jones BS, Marques MB. Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome? J Clin Apher. 2009;24(5):209\u201314.","journal-title":"J Clin Apher"},{"issue":"1","key":"2470_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.12-1-11","volume":"12","author":"KK Francis","year":"2007","unstructured":"Francis KK, Kalyanam N, Terrell DR, Vesely SK, George JN. Disseminated malignancy misdiagnosed as thrombotic thrombocytopenic Purpura: a report of 10 patients and a systematic review of published cases. Oncologist. 2007;12(1):11\u20139.","journal-title":"Oncologist"},{"issue":"4","key":"2470_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","volume":"91","author":"K Lechner","year":"2012","unstructured":"Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012;91(4):195\u2013205.","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"2470_CR13","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1634\/theoncologist.2009-0067","volume":"14","author":"L Oberic","year":"2009","unstructured":"Oberic L, Buffet M, Schwarzinger M, et al. Cancer awareness in atypical thrombotic microangiopathies. Oncologist. 2009;14(8):769\u201379.","journal-title":"Oncologist"},{"issue":"23","key":"2470_CR14","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med"},{"issue":"22","key":"2470_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood.V128.22.136.136","volume":"128","author":"M Grall","year":"2016","unstructured":"Grall M, Prov\u00f4t F, Coindre JP, et al. Efficacy of Eculizumab in gemcitabine-induced thrombotic Microangiopathy: experience of the French thrombotic Microangiopathies reference center. Blood. 2016;128(22):136.","journal-title":"Blood."},{"issue":"10095","key":"2470_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet."},{"key":"2470_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.kint.2019.01.023","volume":"95","author":"A Le Clech","year":"2019","unstructured":"Le Clech A, Simon-Tillaux N, Prov\u00f4t F, et al. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors. Kidney Int. 2019;95:1443.","journal-title":"Kidney Int"},{"issue":"1","key":"2470_CR18","first-page":"E30","volume":"5","author":"O Al Ustwani","year":"2014","unstructured":"Al Ustwani O, Lohr J, Dy G, et al. Eculizumab therapy for gemcitabine induced hemolytic uremic syndrome: case series and concise review. J Gastrointest Oncol. 2014;5(1):E30\u20133.","journal-title":"J Gastrointest Oncol"},{"key":"2470_CR19","doi-asserted-by":"crossref","unstructured":"Starck M, Wendtner C-M. Use of eculizumab in refractory gemcitabine-induced thrombotic microangiopathy. Br J Haematol. 2013.","DOI":"10.1111\/bjh.12686"},{"key":"2470_CR20","first-page":"701","volume":"37","author":"T Rogier","year":"2016","unstructured":"Rogier T, Gerfaud-Valentin M, Pouteil-Noble C, et al. Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report. Rev Med Interne Fondee Par Soc Natl Francaise Med Interne. 2016;37:701.","journal-title":"Rev Med Interne Fondee Par Soc Natl Francaise Med Interne"},{"key":"2470_CR21","first-page":"30178","volume":"1","author":"JL Turner","year":"2016","unstructured":"Turner JL, Reardon J, Bekaii-Saab T, Cataland SR, Arango MJ. Gemcitabine-Associated Thrombotic Microangiopathy: Response to Complement Inhibition and Reinitiation of Gemcitabine. Clin Colorectal Cancer. 2016;1:30178.","journal-title":"Clin Colorectal Cancer"},{"issue":"2","key":"2470_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.5414\/CN108838","volume":"87","author":"ME L\u00f3pez Rubio","year":"2017","unstructured":"L\u00f3pez Rubio ME, Rodado Mart\u00ednez R, Illescas ML, et al. Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports. Clin Nephrol. 2017;87(2):100\u20136.","journal-title":"Clin Nephrol"},{"issue":"6","key":"2470_CR23","doi-asserted-by":"publisher","first-page":"omz048","DOI":"10.1093\/omcr\/omz048","volume":"2019","author":"K Martin","year":"2019","unstructured":"Martin K, Roberts V, Chong G, et al. Eculizumab therapy in gemcitabine-induced thrombotic microangiopathy in a renal transplant recipient. Oxf Med Case Rep. 2019;2019(6):omz048.","journal-title":"Oxf Med Case Rep"},{"issue":"1","key":"2470_CR24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","volume":"19","author":"V Krishnappa","year":"2018","unstructured":"Krishnappa V, Gupta M, Shah H, et al. The use of eculizumab in gemcitabine induced thrombotic microangiopathy. BMC Nephrol. 2018;19(1):9.","journal-title":"BMC Nephrol"},{"issue":"12","key":"2470_CR25","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ccr3.1214","volume":"5","author":"R Gosain","year":"2017","unstructured":"Gosain R, Gill A, Fuqua J, et al. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep. 2017;5(12):1926\u201330.","journal-title":"Clin Case Rep"},{"issue":"1","key":"2470_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13256-017-1373-5","volume":"11","author":"L Facchini","year":"2017","unstructured":"Facchini L, Lucchesi M, Stival A, et al. Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report. J Med Case Rep. 2017;11(1):209.","journal-title":"J Med Case Rep"},{"key":"2470_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/bcp.13808","volume":"85","author":"F Daviet","year":"2019","unstructured":"Daviet F, Rouby F, Poullin P, et al. Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019;85:403\u201312.","journal-title":"Br J Clin Pharmacol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02470-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02470-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:06:18Z","timestamp":1626825978000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02470-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2470"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02470-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"7 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients and\/or parents\/guardians provided written informed consent for entry into the current study. This study was approved by our institutional review board (Rouen University Hospital) in accordance with the Declaration of Helsinki, and the French Data Protection Authority (\u201cCommission Nationale Informatique et Libert\u00e9s,\u201d CNIL, authorization n\u00b0911,539, and \u201cComit\u00e9 consultatif sur le traitement de l\u2019information en mati\u00e8re de recherche dans le domaine de la sant\u00e9,\u201d CCTIRS, authorization n\u00b011.537, Paris, France).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PC, SG and VFB are members of the Clinical Advisory Board for Alexion. PC and YG are members of the Clinical Advisory Board for Sanofi and Octapharma. PC received financings from Roche Pharma. SG received grants from Alexion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"267"}}